{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:22:25Z","timestamp":1791397345065,"version":"4.3.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","revespcardiol.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.rec.2023.12.010","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T08:35:47Z","timestamp":1705826147000},"page":"481-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of initiation of SGLT2 inhibitor treatment on the development of arrhythmias in patients with implantable cardiac devices"],"prefix":"10.1016","volume":"77","author":[{"given":"Carlos","family":"Minguito-Carazo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"S\u00e1nchez Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Rodr\u00edguez Ma\u00f1ero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Mart\u00ednez-Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"Fidalgo Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda Seara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Gonz\u00e1lez Rebollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rodr\u00edguez Santamarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Gonz\u00e1lez Melchor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teba","family":"Gonz\u00e1lez Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Romero Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Alberto","family":"Fern\u00e1ndez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tundidor Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Fern\u00e1ndez V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2023.12.010_bib0150","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2023.12.010_bib0155","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2023.12.010_bib0160","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2023.12.010_bib0165","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2023.12.010_bib0170","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2023.12.010_bib0175","first-page":"E895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2023.12.010_bib0180","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Hear Rhythm."},{"key":"10.1016\/j.rec.2023.12.010_bib0185","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jce.15894","article-title":"SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta-analysis of randomized clinical trials","volume":"34","author":"Oates","year":"2023","journal-title":"J Cardiovasc Electrophysiol."},{"key":"10.1016\/j.rec.2023.12.010_bib0190","first-page":"20","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials","volume":"24","author":"Sfairopoulos","year":"2022","journal-title":"EP Eur."},{"key":"10.1016\/j.rec.2023.12.010_bib0195","first-page":"1","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rec.2023.12.010_bib0200","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/jce.15996","article-title":"Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy-arrhythmia burden in patients with cardiac implantable electronic devices","volume":"34","author":"Younis","year":"2023","journal-title":"J Cardiovasc Electrophysiol."},{"key":"10.1016\/j.rec.2023.12.010_bib0205","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2023.12.010_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rec.2023.12.010_bib0215","doi-asserted-by":"crossref","first-page":"e022222","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-glucose co-transporter inhibitors and atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.rec.2023.12.010_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01048-x","article-title":"The association between SGLT2 inhibitors and new-onset arrhythmias: A nationwide population-based longitudinal cohort study","volume":"19","author":"Chen","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rec.2023.12.010_bib0225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ehjcvp\/pvac043","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus","volume":"9","author":"Eroglu","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"10.1016\/j.rec.2023.12.010_bib0230","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2023.12.010_bib0235","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cjca.2022.01.016","article-title":"Ventricular Tachycardia Burden and Mortality: Association or Causality?","volume":"38","author":"Samuel","year":"2022","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.rec.2023.12.010_bib0240","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Hear Fail."},{"key":"10.1016\/j.rec.2023.12.010_bib0245","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium\/Glucose Cotransporter 2 Inhibitor Empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2023.12.010_bib0250","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis\/Stiffness in Nondiabetic Heart Failure: A Multimodality Study","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"JACC Cardiovasc Imaging."},{"key":"10.1016\/j.rec.2023.12.010_bib0255","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic Insights of Empagliflozin in Nondiabetic Patients with HFrEF: from the EMPA-TROPISM Study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Hear Fail."},{"key":"10.1016\/j.rec.2023.12.010_bib0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.hrthm.2022.10.009","article-title":"Reduction in atrial and pulmonary vein stretch as a therapeutic target for prevention of atrial fibrillation","volume":"20","author":"Gottlieb","year":"2023","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.rec.2023.12.010_bib0265","first-page":"1052","article-title":"Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die","volume":"24","author":"Lim","year":"2022","journal-title":"EP Eur."},{"key":"10.1016\/j.rec.2023.12.010_bib0270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci."},{"key":"10.1016\/j.rec.2023.12.010_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: The EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rec.2023.12.010_bib0280","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ahj.2022.01.008","article-title":"Ertugliflozin to reduce arrhythmic burden in ICD\/CRT patients (ERASe-trial) - A phase III study","volume":"246","author":"von Lewinski","year":"2022","journal-title":"Am Heart J."},{"key":"10.1016\/j.rec.2023.12.010_bib0285","unstructured":"Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation. ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04792190. Accessed 3 May 2023."},{"key":"10.1016\/j.rec.2023.12.010_bib0290","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol."}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585724000264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585724000264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T11:23:51Z","timestamp":1716463431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585724000264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1885585724000264"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2023.12.010","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of initiation of SGLT2 inhibitor treatment on the development of arrhythmias in patients with implantable cardiac devices","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.recesp.2023.12.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}